Overview of the Epidemiology, Diagnosis, and Disease Progression Associated With Multiple Sclerosis

被引：0

作者：

Tullman, Mark J. ^{[1
]}

机构：

[1] Missouri Baptist Med Ctr, MS Ctr Innovat Care, St Louis, MO 63131 USA

来源：

AMERICAN JOURNAL OF MANAGED CARE | 2013年 / 19卷 / 02期

关键词：

DACLIZUMAB; DISABILITY; CRITERIA; THERAPY; LESIONS; CELLS;

D O I：

暂无

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Multiple sclerosis.(MS) is a chronic inflammatory demyelinating disease of the central nervous system that affects approximately 400,000 people in the United States. The etiology of MS is unknown, but it is likely the result of a complex interaction between genetic and environmental factors and the immune system. The clinical manifestations of MS are highly variable, but most patients initially experience a relapsing-remitting course. Patients accumulate disability as a result of incomplete recovery from acute exacerbations and/or gradual disease progression. This article briefly reviews the immunopathology of MS, the symptoms and natural course of the disease, and the recently revised MS diagnostic criteria. (Am J Manag Care. 2013;19:S15-S20)

引用

页码：S15 / S20

页数：6

共 23 条

[1]

Berger Joseph R, 2011, Am J Manag Care, V17 Suppl 5 Improving, pS146

[2] Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].

Bielekova, B ;

Goodwin, B ;

Richert, N ;

Cortese, I ;

Kondo, T ;

Afshar, G ;

Gran, B ;

Eaton, J ;

Antel, J ;

Frank, JA ;

McFarland, HF ;

Martin, R .

NATURE MEDICINE, 2000, 6 (10) :1167-1175

[3] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].

Bielekova, B ;

Catalfamo, M ;

Reichert-Scrivner, S ;

Packer, A ;

Cerna, M ;

Waldmann, TA ;

McFarland, H ;

Henkart, PA ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946

[4] Natural history of multiple sclerosis: a unifying concept [J].

Confavreux, C ;

Vukusic, S .

BRAIN, 2006, 129 :606-616

[5] Relapses and progression of disability in multiple sclerosis. [J].

Confavreux, C ;

Vukusic, S ;

Moreau, T ;

Adeleine, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) :1430-1438

[6] Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis [J].

Fisniku, L. K. ;

Brex, P. A. ;

Altmann, D. R. ;

Miszkiel, K. A. ;

Benton, C. E. ;

Lanyon, R. ;

Thompson, A. J. ;

Miller, D. H. .

BRAIN, 2008, 131 :808-817

[7] Medical progress: Multiple sclerosis - The plaque and its pathogenesis [J].

Frohman, EM ;

Racke, MK ;

Raine, CS .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :942-955

[8] Oxidative damage in multiple sclerosis lesions [J].

Haider, Lukas ;

Fischer, Marie T. ;

Frischer, Josa M. ;

Bauer, Jan ;

Hoeftberger, Romana ;

Botond, Gergoe ;

Esterbauer, Harald ;

Binder, Christoph J. ;

Witztum, Joseph L. ;

Lassmann, Hans .

BRAIN, 2011, 134 :1914-1924

[9]

Kaur G., 2013, Brain

[10] The changing demographic pattern of multiple sclerosis epidemiology [J].

Koch-Henriksen, Nils ;

Sorensen, Per Soelberg .

LANCET NEUROLOGY, 2010, 9 (05) :520-532

← 1 2 3 →